TG Therapeutics' Q3 earnings missed EPS expectations despite Briumvi's revenue growth. See why TGTX stock is a Buy.

Roche has said it plans to UK price its latest multiple sclerosis drug Ocrevus in line with its close rival from Novartis - aiming to undercut some established rivals. Approved in Europe earlier ...

Roche's key products like Vabysmo, Ocrevus, and Phesgo are performing well. Read why RHHBY stock looks well positioned to ...

Ocrevus is a medicine commonly used to treat primary progressive MS, but it can take up to four hours to receive intravenously. A new version called “Ocrevus Zunovo” was recently approved by ...

Roche has secured approval from the US Food and Drug Administration (FDA) for Ocrevus Zunovo (ocrelizumab and ...

Ocrevus sales increased 11% to 1.69 billion Swiss francs, while Vabysmo surged 59%. On Wednesday, Roche Holdings AG RHHBY released its third-quarter sales report. Sales increased 9% year over year ...

Roche said it would increase its dividend after its hemophilia injection Hemlibra and multiple sclerosis treatment Ocrevus ...

Following NICE's rejection of Ocrevus in PPMS, more than 21,000 patients had signed a petition calling for a rethink, and more than 3,000 people raised the issue with their local MP, the MS ...

“Just a little better quality of life.” As the availability of Ocrevus Zunuvo continues to increase across the country, Josh Weber, UVA Health’s director of specialty and home pharmacy ...

(WRIC) – The University of Virginia’s (UVA) health system has become one of the first in the country to administer a groundbreaking FDA-approved drug, Ocrevus Zunovo, to patients with ...

The FDA has approved three such drugs for MS. Ocrelizumab (Ocrevus) treats relapsing forms of MS, including: Clinically isolated syndrome Relapsing-remitting MS Active secondary progressive MS in ...

On Wednesday, Roche Holdings AG (OTC:RHHBY) released its third-quarter sales report. Sales increased 9% year over year to ...